Zetia/Zocor Market Will Be First-Line Patients, Not Switches, Merck Says

Merck/Schering's Zetia/Zocor fixed-dose combination will be positioned as a first-line, cholesterol-lowering therapy, while Zetiawill be reserved primarily for the niche population of patients who are not at their target cholesterol levels